Nivolumab-induced Diaphragm Dysfunction: A Case Report.
1Department of Intensive Care Medicine, Amsterdam University Medical Centers, Amsterdam, North Holland, Netherlands.
Summary
Nivolumab immunotherapy can cause severe diaphragm dysfunction, a rare but serious side effect. Clinicians should consider this complication in patients on nivolumab experiencing shortness of breath, and ultrasound can aid diagnosis.
Area of Science:
- Immunology
- Pulmonology
- Oncology
Background:
- Nivolumab is a widely used immune checkpoint inhibitor for melanoma treatment.
- While effective, nivolumab can cause immune-related adverse events affecting various organ systems.
- Diaphragm dysfunction is a potential, albeit uncommon, complication of nivolumab therapy.
Observation:
- A case report details a patient experiencing severe diaphragm dysfunction during nivolumab treatment for melanoma.
- The patient presented with dyspnea, a common symptom that can be indicative of diaphragm impairment.
- This highlights a critical side effect that may be underrecognized.
Findings:
- Nivolumab therapy was directly linked to the development of severe diaphragm dysfunction in this patient.
- The case underscores the potential for nivolumab to impact neuromuscular function.
- Diaphragm dysfunction can lead to significant respiratory compromise.
Implications:
- As nivolumab use expands, clinicians must be vigilant for diaphragm dysfunction in patients with dyspnea.
- Early recognition and diagnosis are crucial for appropriate management.
- Ultrasound offers a practical and accessible tool for assessing diaphragm function in affected patients.
More Related Videos
Related Concept Videos
01:27Pneumothorax-II
243
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Clinical Manifestations:
243
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
228
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
228
01:26Pneumothorax-I
280
A pneumothorax is a condition where air builds up in the space between the lung and the chest wall, causing the lung to collapse. This condition arises when air enters the space between the parietal and visceral pleura, disrupting the negative pressure essential for lung inflation. This can lead to a partial or complete collapse of the lung.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
280
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
394
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
394
01:21Barrett Esophagus-II: Clinical Manifestations and Management
246
Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
246
01:28Esophageal Perforation-II: Clinical Manifestations and Management
115
Esophageal perforations manifest in various clinical forms, influenced by factors such as the perforation's cause and location (cervical, intrathoracic, or intra-abdominal), the extent of contamination, and potential injury to adjacent mediastinal structures. The timing between the perforation occurrence and treatment initiation also affects the clinical presentation.
Clinical Manifestations:
Clinical Manifestations:
115